A market analysis and clinical commentary on the growing threat of invasive fungal infections
I. The Unseen Market
India's antifungal drug market rarely attracts attention. Valued at an estimated ₹4,000–₹6,500 crore, it operates largely beneath the radar of policy discussions and pharmaceutical strategy. Yet its growth trajectory reflects profound shifts in the country's disease burden and hospital practice—shifts that clinicians may not yet fully recognise.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
